Clinical Trials Browser

Ovarian Neoplasms × tremelimumab × 1 year × Clear all

NCT03026062 2025-09-19

Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Completed

Fallopian Tube Neoplasms, Ovarian Neoplasms